Fleming TR - Search Results

1

Fleming TR, DeGruttola V, DeMets DL. Fleming TR, et al. AIDS Clin Rev. 1997-1998:129-43. AIDS Clin Rev. 1997. PMID: 9305447 Review. No abstract available.

2

Surrogate end points in clinical trials: are we being misled?

Fleming TR, DeMets DL. Fleming TR, et al. Ann Intern Med. 1996 Oct 1;125(7):605-13. doi: 10.7326/0003-4819-125-7-199610010-00011. Ann Intern Med. 1996. PMID: 8815760 Review. No abstract available.

3

Estimating the proportion of treatment effect explained by a surrogate marker.

Lin DY, Fleming TR, De Gruttola V. Lin DY, et al. Among authors: fleming tr. Stat Med. 1997 Jul 15;16(13):1515-27. doi: 10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1. Stat Med. 1997. PMID: 9249922

4

Monitoring of clinical trials: issues and recommendations.

Fleming TR, DeMets DL. Fleming TR, et al. Control Clin Trials. 1993 Jun;14(3):183-97. doi: 10.1016/0197-2456(93)90002-u. Control Clin Trials. 1993. PMID: 8339549 Review.

5

Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Fleming TR, Neaton JD, Goldman A, DeMets DL, Launer C, Korvick J, Abrams D. Fleming TR, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S9-18. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552519 Clinical Trial.

6

COVID-19 vaccine trials should seek worthwhile efficacy.

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R; World Health Organization Solidarity Vaccines Trial Expert Group. Krause P, et al. Among authors: fleming tr. Lancet. 2020 Sep 12;396(10253):741-743. doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27. Lancet. 2020. PMID: 32861315 Free PMC article. No abstract available.

7

The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.

DeMets DL, Fleming TR, Whitley RJ, Childress JF, Ellenberg SS, Foulkes M, Mayer KH, O'Fallon J, Pollard RB, Rahal JJ, et al. DeMets DL, et al. Among authors: fleming tr. Control Clin Trials. 1995 Dec;16(6):408-21. doi: 10.1016/s0197-2456(95)00073-9. Control Clin Trials. 1995. PMID: 8720018 Free article.

8

Surrogate markers in AIDS and cancer trials.

Fleming TR. Fleming TR. Stat Med. 1994 Jul 15-30;13(13-14):1423-35; discussion 1437-40. doi: 10.1002/sim.4780131318. Stat Med. 1994. PMID: 7973222 Review.

9

Surrogate end points in cardiovascular disease trials.

Fleming TR. Fleming TR. Am Heart J. 2000 Apr;139(4):S193-6. doi: 10.1016/s0002-8703(00)90071-1. Am Heart J. 2000. PMID: 10740130 No abstract available.

10

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.

Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Psaty BM, et al. Among authors: fleming tr. JAMA. 1999 Aug 25;282(8):786-90. doi: 10.1001/jama.282.8.786. JAMA. 1999. PMID: 10463718 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

225 results

Search Page